New Triple-Threat treatment tested for Tough-to-Treat cancers
NCT ID NCT04708470
Summary
This study is testing a new combination of three immunotherapy drugs for people with advanced cancers that have not responded well to standard treatments. It focuses on cancers linked to HPV (like cervical, throat, and anal cancers) and certain colon cancers. The main goals are to find a safe dose and see if the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.